# Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers

> **NCT01500408** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 110 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Interferon beta-1a (current approved manufacturing process invloving FBS)
- **DRUG:** Interferon beta-1a (new process, manufactured without FBS)

## Key facts

- **NCT ID:** NCT01500408
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2012-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01500408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01500408, "Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01500408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*